Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MedAvail Holdings, Inc.MYOS · Entity 94590 | Director | March 31, 2020 | April 06, 2020 |
| TriSalus Life Sciences, Inc.MTAC · Entity 5872 | 10% owner | June 26, 2023 | June 27, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MedAvail Holdings, Inc.
Report date March 31, 2020 · Filed April 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 328,982 |
Reported balance
After 2020-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-03-31 · Purchase · Acquired 6,611 · Balance 328,982 F1: The shares of common stock were awarded to the reporting person under the registrant's 2012 Equity Incentive Plan and will vest immediately. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock were awarded to the reporting person under the registrant's 2012 Equity Incentive Plan and will vest immediately.
TriSalus Life Sciences, Inc.
Report date June 26, 2023 · Filed June 27, 2023
Jointly reported with MedTech Acquisition Sponsor LLC, MATLIN DAVID J
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 6,249,999 |
Reported balance
After 2023-06-26 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-06-26 · Conversion · Acquired 6,249,999 · Balance 6,249,999 F1: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F2: The Sponsor is the record holder of the securities reported herein. Christopher C. Dewey and David J. Matlin are managing members of the Sponsor. By virtue of this relationship, each of these individuals may be deemed to share beneficial ownership of the securities held of record by the Sponsor. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 1 |
Reported balance
After 2023-06-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-26 · Conversion · Disposed 6,249,999 · Balance 1 F1: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F2: The Sponsor is the record holder of the securities reported herein. Christopher C. Dewey and David J. Matlin are managing members of the Sponsor. By virtue of this relationship, each of these individuals may be deemed to share beneficial ownership of the securities held of record by the Sponsor. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock.
F2: The Sponsor is the record holder of the securities reported herein. Christopher C. Dewey and David J. Matlin are managing members of the Sponsor. By virtue of this relationship, each of these individuals may be deemed to share beneficial ownership of the securities held of record by the Sponsor. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2023 Filed Jun 27, 2023 20:13 UTC | TriSalus Life Sciences, Inc. MTAC · Entity 5872 | ConversionClass B Common Stock · Derivative | 6,249,999 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-075256 · tm2319584-1_4seq1.xml · derivative · entry 2 MedTech Acquisition Sponsor LLC · CIK 0001826760 · 10% owner Dewey Christopher C · CIK 0001385015 · 10% owner MATLIN DAVID J · CIK 0001251956 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1 Underlying: Class A Common Stock · 6,249,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F1 · kind: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F1 · price: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F1 · derivative.exercise_date: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F1 · derivative.expiration_date: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. Christopher C. Dewey and David J. Matlin are managing members of the Sponsor. By virtue of this relationship, each of these individuals may be deemed to share beneficial ownership of the securities held of record by the Sponsor. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interest therein. Read SEC document |
| June 26, 2023 Filed Jun 27, 2023 20:13 UTC | TriSalus Life Sciences, Inc. MTAC · Entity 5872 | ConversionClass A Common Stock | 6,249,999 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-075256 · tm2319584-1_4seq1.xml · nonDerivative · entry 1 MedTech Acquisition Sponsor LLC · CIK 0001826760 · 10% owner Dewey Christopher C · CIK 0001385015 · 10% owner MATLIN DAVID J · CIK 0001251956 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,249,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F1 · price: The shares of Class B common stock, par value $0.0001 per share ("Class B Common Stock"), of the issuer are convertible into an equal number of shares of Class A common stock, par value $0.0001 per share ("Class A Common Stock"), of the issuer. On June 26, 2023, MedTech Acquisition Sponsor LLC (the "Sponsor") elected to convert 6,249,999 shares of their Class B Common Stock into an equal number of Class A Common Stock. F2 · ownership.direct: The Sponsor is the record holder of the securities reported herein. Christopher C. Dewey and David J. Matlin are managing members of the Sponsor. By virtue of this relationship, each of these individuals may be deemed to share beneficial ownership of the securities held of record by the Sponsor. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interest therein. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 12:28 UTC | TriSalus Life Sciences, Inc. MTACU · Entity 5872 | OtherClass B Common Stock · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-139621 · tm2039407d1_4.xml · derivative · entry 1 Dewey Christopher C · CIK 0001385015 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 6,250,000 Underlying: Class A Common Stock · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the Issuer's initial business combination on a one-for-one basis. The Class B common stock has no expiration date. F2 · kind: As contemplated in connection with the initial public offering of the Issuer, 75,000 shares of Class B common stock of the Issuer were returned by the reporting person to the Issuer for no consideration and cancelled because the underwriters' over-allotment option was not exercised in full. F1 · derivative.exercise_date: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the Issuer's initial business combination on a one-for-one basis. The Class B common stock has no expiration date. F1 · derivative.expiration_date: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the Issuer's initial business combination on a one-for-one basis. The Class B common stock has no expiration date. F3 · ownership.nature: MedTech Acquisition Sponsor LLC ("Sponsor") is the record holder of the securities reported herein. Christopher C. Dewey is a managing member of the Sponsor and may be deemed to have beneficial ownership of the securities held of record by Sponsor. Mr. Dewey disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| March 31, 2020 Filed Apr 6, 2020 21:11 UTC | MedAvail Holdings, Inc. MYOS · Entity 94590 | PurchaseCommon Stock | 6,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-008709 · ownership.xml · nonDerivative · entry 1 Dewey Christopher C · CIK 0001385015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,982 F1 · balance_after: The shares of common stock were awarded to the reporting person under the registrant's 2012 Equity Incentive Plan and will vest immediately. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 17:03 UTC | MedAvail Holdings, Inc. MYOS · Entity 94590 | PurchaseCommon Stock | 82,645 | $1.21 | $100,000.45 |
DisclosureSEC source: 0001213900-20-005777 · ownership.xml · nonDerivative · entry 1 Dewey Christopher C · CIK 0001385015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,371 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.